Rifamycin sodium CR is under clinical development by Cosmo Pharmaceuticals and currently in Phase II for Hepatic Encephalopathy. According to GlobalData, Phase II drugs for Hepatic Encephalopathy have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Rifamycin sodium CR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rifamycin sodium CR overview

Rifamycin sodium (Aemcolo, Relafalk) is an anti-infective agent. It is formulated as controlled release film coated tablets, tablets for oral route of administration. Aemcolo is indicated for the treatment of adult patients with traveler's diarrhea caused by non-invasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.

Rifamycin SV MMX is under development for the treatment of diarrhoea predominant irritable bowel syndrome (IBS-D), uncomplicated diverticulitis, minimal hepatic encephalopathy and small intestine bacterial overgrowth (SIBO) and traveler's diarrhea in adolescents of 12 to 17 years. It was also under development for the treatment of infectious colitis, and infectious diarrhea.

Cosmo Pharmaceuticals overview

Cosmo Pharmaceuticals (Cosmo) develops drugs for the treatment of gastrointestinal diseases and dermatology. It develops pharmaceutical products based on its multi-matrix technology. The company offers products such as Lialda, Mezavant, Mesavancol and Uceris for the treatment of ulcerative colitis. It also offers Eleview which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures. The company’s manufacturing facility is located in Lainate, Milan. Cosmo is headquartered in Dublin, Ireland.

For a complete picture of Rifamycin sodium CR’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.